MicroRNA and alternative mRNA splicing events in cancer drug response/resistance: potent therapeutic targets
Cancer is a multifaceted disease that involves several molecular mechanisms including
changes in gene expression. Two important processes altered in cancer that lead to …
changes in gene expression. Two important processes altered in cancer that lead to …
Unique role of DDX41, a DEAD-box type RNA helicase, in hematopoiesis and leukemogenesis
S Shinriki, H Matsui - Frontiers in oncology, 2022 - frontiersin.org
In myeloid malignancies including acute myeloid leukemia (AML) and myelodysplastic
syndromes (MDS), patient selection and therapeutic strategies are increasingly based on …
syndromes (MDS), patient selection and therapeutic strategies are increasingly based on …
Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax
Abstract Spliceosome mutations (SRSF2, SF3B1, U2AF1, ZRSR2), are encountered in∼
50% of secondary acute myeloid leukemia cases (sAML) and define a molecular subgroup …
50% of secondary acute myeloid leukemia cases (sAML) and define a molecular subgroup …
[HTML][HTML] Functional analyses of human LUC7-like proteins involved in splicing regulation and myeloid neoplasms
Vertebrates have evolved three paralogs, termed LUC7L, LUC7L2, and LUC7L3, of the
essential yeast U1 small nuclear RNA (snRNA)-associated splicing factor Luc7p. We …
essential yeast U1 small nuclear RNA (snRNA)-associated splicing factor Luc7p. We …
Increased chromatin accessibility facilitates intron retention in specific cell differentiation states
V Petrova, R Song, DEEP Consortium… - Nucleic Acids …, 2022 - academic.oup.com
Dynamic intron retention (IR) in vertebrate cells is of widespread biological importance.
Aberrant IR is associated with numerous human diseases including several cancers …
Aberrant IR is associated with numerous human diseases including several cancers …
Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease
Myelodysplastic syndromes (MDS) are a heterogeneous clonal disease of myeloid
neoplasms characterized by ineffective hematopoiesis, variable degree of cytopenias, and …
neoplasms characterized by ineffective hematopoiesis, variable degree of cytopenias, and …
[HTML][HTML] Alternative splicing events and function in the tumor microenvironment: New opportunities and challenges
X Song, X Li, Y Ge, J Song, Q Wei, M He… - International …, 2023 - Elsevier
Alternative splicing controls gene expression at the transcriptional level, producing
structurally and functionally distinct protein heterodimers. Aberrant alternative splicing …
structurally and functionally distinct protein heterodimers. Aberrant alternative splicing …
[HTML][HTML] Discovery of U2AF1 neoantigens in myeloid neoplasms
MA Biernacki, J Lok, RG Black, KA Foster… - … for Immunotherapy of …, 2023 - ncbi.nlm.nih.gov
Background Myelodysplastic syndromes (MDS) arise from somatic mutations acquired in
hematopoietic stem and progenitor cells, causing cytopenias and predisposing to …
hematopoietic stem and progenitor cells, causing cytopenias and predisposing to …
Small molecule inhibition of RNA binding proteins in haematologic cancer
AK Jaiswal, ML Thaxton, GM Scherer, JP Sorrentino… - RNA biology, 2024 - Taylor & Francis
In recent years, advances in biomedicine have revealed an important role for post-
transcriptional mechanisms of gene expression regulation in pathologic conditions. In …
transcriptional mechanisms of gene expression regulation in pathologic conditions. In …
The eukaryotic translation initiation factor eIF4E reprograms alternative splicing
Aberrant splicing is typically attributed to splice‐factor (SF) mutation and contributes to
malignancies including acute myeloid leukemia (AML). Here, we discovered a mutation …
malignancies including acute myeloid leukemia (AML). Here, we discovered a mutation …